Erik Digman Wiklund

Opinion author

Erik Digman Wiklund is CEO of Circio. He has deep scientific knowledge in RNA and cancer biology and 13 years of pharma and biotech industry experience in a variety of functions including R&D, finance and business development. Wiklund holds a PhD in molecular biology from Aarhus University in Denmark and the Garvan Institute of Medical Research in Sydney, Australia.

illustration of a circular RNA molecule and IV bags

Opinion

Circular RNA Will Soon Replace mRNA in Biopharma

The advantages of using circular RNAs—including increased durability, enhanced protein expression and substantially lower manufacturing costs compared to linear mRNAs—have driven a spate of investment in this technology.

July 31, 2024

5 min read

Erik Digman Wiklund